- 회사소개
- 연구개발
- 사업분야
- IR / PR
- 공지사항
R & D
COVID-19 vaccine (EG-COVID)
COVID-19 vaccine (EG-COVID) Overview
- Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2 virus. Common symptoms include mild symptoms such as fever, boredom, cough, sore throat, breathing difficulties to severe respiratory infections such as shortness of breath and pneumonia.
EG-COVID Highlights
In vivo Efficacy
-
EG-R system effectively deliver mRNA
- mRNA complexed with EG-R is expressed in vivo similarly to that with LNPs
- EG-R does not spread throughout the body, showing a local depot effect
-
EG-COVID Cross-reactivity
- EG-COVID may protect alpha and beta variant as well as wild type strain
-
Stability of freeze-dried formulation
- Freeze-dried formulation of EG-COVID is stable for 8 weeks in refrigerated condition
- T. +82-2-322-1687
- F. +82-2-302-4359 / +82-2-324-8059
- 본사 : [07528] 서울특별시 강서구 양천로 401 강서한강자이타워 B동 1211호
- 연구소 : [10551] 경기도 고양시 덕양구 의장로 122-1 2층
COPYRIGHTⓒ 2019 EYEGENE lnc. LTD. All RIGHTS RESERVED.
